Details

Autor(en) / Beteiligte

• Chen, Yin-Kai
• Hou, Hsin-An
• Tang, Jih-Luh
• Jhuang, Jie-Yang
• Lai, Yan-Jun
• Lee, Ming-Cheng
• Kuo, Yuan-Yeh
• Chou, Wen-Chien
• Liu, Chieh-Yu
• Lin, Chung-Wu
• Chuang, Shih-Sung
• Chen, Chien-Yuan
• Tseng, Mei-Hsuan
• Huang, Chi-Fei
• Chiang, Ying-Chieh
• Lee, Fen-Yu
• Liu, Ming-Chih
• Liu, Chia-Wen
• Yao, Ming
• Huang, Shang-Yi
• Ko, Bor-Sheng
• Hsu, Szu-Chun
• Wu, Shang-Ju
• Tsay, Woei
• Chen, Yao-Chang
• Tien, Hwei-Fang
• Böenig, Halvard

Titel

Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia

Ist Teil von

• PloS one, 2015-03, Vol.10 (3), p.e0119831-e0119831

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Robo4 is involved in hematopoietic stem/progenitor cell homeostasis and essential for tumor angiogenesis. Expression of Robo4 was recently found in solid tumors and leukemia stem cells. However, the clinical implications of Robo4 expression in patients with acute myeloid leukemia (AML) remain unclear. We investigated the clinical and prognostic relevance of mRNA expression of Robo4 in bone marrow (BM) mononuclear cells from 218 adult patients with de novo AML. We also performed immunohistochemical staining to assess the Robo4 protein expression in the BM biopsy specimens from 30 selected AML patients in the cohort. Higher Robo4 expression was closely associated with lower white blood cell counts, expression of HLA-DR, CD13, CD34 and CD56 on leukemia cells, t(8;21) and ASXL1 mutation, but negatively correlated with t(15;17) and CEBPA mutation. Compared to patients with lower Robo4 expression, those with higher expression had significantly shorter disease-free survival (DFS) and overall survival (OS). This result was confirmed in an independent validation cohort. Furthermore, multivariate analyses showed that higher Robo4 expression was an independent poor prognostic factor for DFS and OS in total cohort and patients with intermediate-risk cytogenetics, irrespective of age, WBC count, karyotype, and mutation status of NPM1/FLT3-ITD, and CEBPA. BM Robo4 expression can serve as a new biomarker to predict clinical outcomes in AML patients and Robo4 may serve as a potential therapeutic target in patients with higher Robo4 expression.